Convira Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Convira Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, gr…

2012-01-30 Kanpur, Uttar Pradesh Active Unlisted Active Compliant
Share
View plans Plan
CP Convira Pharmaceuticals Private Limited
View plans Plan
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Convira Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
83/100
Trust Score
Low Risk

Convira Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 83/100. Convira Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2012, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 14 Jul 2026 from the latest processed filings. Convira Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (9.50 Lakh) · 1 satisfied (20.00 Lakh).

Banking relationships (from registered charges)
LenderChargesAmount
Bank Of India1 48.0 cr
Others1 48.0 cr
Compliance Score: 93/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
PAYAL SAHU 01234567 Director 01/04/2018 6 yrs Approved
SUJEET SAHU 01234567 Director 01/04/2018 6 yrs Approved
Rajesh Sahu 01234567 Director 01/04/2018 6 yrs Approved
Brijesh Kumar Sahu 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: SUJEET SAHU (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 75
Growth signals & trust indicators
Operating for 14+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
1 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence85/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 9.50 Lakh already registered.
  • Compliance record supports lending.
Investor view58/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 13 events
30 Sep 2025
Last AGM held
Annual general meeting
01 Apr 2025
Director appointed
Rajesh Sahu (Director)
Director appointed
Brijesh Kumar Sahu (Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
27 Sep 2021
Charge created
Others - 9.50 Lakh
22 May 2019
Charge satisfied
Bank Of India
16 Jun 2014
Director ceased
BRIJESH AGNIHOTRI
27 Jul 2013
Charge created
Bank Of India - 20.00 Lakh
31 Jan 2012
Securities allotted
1000.00 Equity Shares - 10,000.00 raised
Director ceased
SUJEET SAHU
30 Jan 2012
Incorporated
Registered with Roc Kanpur
Director appointed
PAYAL SAHU (Director)
Director appointed
SUJEET SAHU (Managing Director)
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Sameet Technologies Private Limited U29100PN2020PTC192423 Pune, Maharashtra, India
Secom Services India Private Limited U72100DL2000PTC105834 New Delhi, Delhi, India
Cold Storage & General Mills Pvt Ltd U63022MP1946PTC000308 Gwalior, Madhya Pradesh, India
Goodluck Sales Private Limited U51909CT2009PTC009681 Raipur, Chattisgarh, India
Shree Matre Trading Private Limited U51909TG2020PTC146292 Hyderabad, Telangana, India
Sampling House Private Limited U51909HR2020PTC088153 Gurugram, Haryana, India
Ananda Industries Private Limited U15209DL2003PTC121214 New Delhi, Delhi, India
Dileep Ceramics Private Limited U36998DL2003PTC120738 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Convira Pharmaceuticals Private Limited before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Convira Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Convira Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether Convira Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Convira Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Convira Pharmaceuticals Private Limited an active company?

Convira Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 93/100 (Low Risk).

Is Convira Pharmaceuticals Private Limited financially healthy?

Convira Pharmaceuticals Private Limited has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.

Should I do business with Convira Pharmaceuticals Private Limited?

Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Convira Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Convira Pharmaceuticals Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Convira Pharmaceuticals Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).

Is it risky to lend to Convira Pharmaceuticals Private Limited?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.